Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients

Yi-Shan Tsai, Po-Cheng Liang, Pei-Chien Tsai, Ming-Lun Yeh, Chung-Feng Huang, Meng-Hsuan Hsieh, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Shinn-Cheng Chen, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, and Ming-Lung Yu

Abstract: HCC, a leading cause of cancer-related mortality, is diagnosed at advanced stages. Although antiviral therapy has reduced the risk of HCC among chronic hepatitis C (CHC) patients, the risk of HCC remains, thus, highlighting the unmet need for continuous surveillance. Therefore, stable and cost-effective biomarkers, such as circulating microRNAs, must be identified. We aimed to clarify whether serum levels of the Let-7 family can predict HCC risk in patients with CHC. We assessed the sera of 54 patients with CHC who developed HCC and 173 patients with CHC who did not develop HCC after antiviral therapy. Cox’s regression model revealed the independent role of let-7i as an effective surrogate biomarker for predicting HCC development in patients with CHC.
Keywords: chronic hepatitis C; Let-7 family; hepatitis C virus; miRNA; biomarker; hepatocellular carcinoma; post-sustained virologic response

1. Introduction

Chronic hepatitis C (CHC) virus infection is a major cause of advanced liver disease and hepatocellular carcinoma (HCC) worldwide. The annual HCC risk continues to be >2% for up to 10 years after the sustained virologic response (SVR) in CHC patients with cirrhosis and a Fibrosis-4 (FIB-4) score of \( \geq 3.25 \) [1]. Hepatitis C (HCV)-infected patients have a 17-fold increased risk of developing HCC [2]. Cost-effective, HCC risk-based surveillance strategies should be established after SVR. HCV eradication with interferon and ribavirin therapy decreased the incidence of new-onset liver cancer in non-cirrhotic patients and the incidence of liver-related complications (decompensated liver disease or hepatocellular carcinoma) in cirrhotic patients with CHC [3]. Ultrasound (US)-based transient elastography, although widely available, low-cost, and user-friendly compared to computed tomography (CT) and magnetic resonance imaging (MRI), is not a sensitive predictor of early fibrosis [4]. Clinical markers, such as age, alanine aminotransferase, alpha-fetoprotein (AFP), and platelets, have been proposed to give a rough estimate of the risk of HCC. However, approximately 32–59% of patients with HCC have normal AFP levels; moreover, non-tumor-related AFP elevations may occur in patients with cirrhosis or chronic hepatitis, making AFP an inappropriate marker in surveillance [5].

MicroRNAs (miRNAs) are non-coding RNAs that post-transcriptionally modulate gene expression by affecting the stability and translation of complementary mRNAs. miRNAs repress essential HCV co-factors [6]. The members of the Let-7 family, miR-92, miR-122, miR-125b, mir-143, miR-192, miR-16, miR-126, and miR-199a/b have been found in normal livers and participate in the development of fibrogenesis and HCC [7,8]. The Let-7 family also includes 12 miRNA members, which are involved in the negative regulation of onco-genes and cell cycle regulators known as tumor suppressors [9,10]. The Let-7 family can be described by three distinct clusters of highly correlated expression in the circulating system [11]. Circulating Let-7 levels in plasma are correlated with hepatic fibrosis progression in CHC patients [12], and circulating microRNAs are considered stable serum markers for early cancer diagnosis, and to predict prognosis and response to therapy [13]. From systematic review and meta-analysis studies, it is clear that the circulation of specific aberrant miRNAs in the blood may increase the risk of HCC, and miRNAs could be utilized for the early diagnosis of HCC [14].

Interestingly, the role of the circulating Let-7 family members in HCC development in CHC patients after antiviral treatment has rarely been explored. Here, we conducted a longitudinal follow-up study with a well-characterized HCV cohort after antiviral therapy with and without SVR to determine the role of the circulating Let-7 family members in the prediction of HCC development.

2. Materials and Methods

2.1. Patient Cohort

Fifty-four patients with CHC who developed HCC after antiviral therapy (defined as the de novo HCC group, Table S1) and 173 patients with CHC who did not develop HCC after antiviral therapy were enrolled in the study. The patients were positive for anti-HCV antibody for more than 6 months and were found to be positive for HCV RNA using polymerase chain reaction (PCR) assay. The patients achieved an SVR and showed undetectable HCV RNA after 24 weeks (M6) of peginterferon/ribavirin treatment. The exclusion criteria were a history of hepatitis B surface antigen, concomitant human immunodeficiency virus infection, other types of hepatitis, daily ethanol consumption \( \geq 20 \) g (females and males), and no evidence of HCC before, during, or within 6 months of starting the antiviral therapy. FIB-4 was defined by the following equation:
(age × AST [U/L])/(PLT [10^9]/L × ALT [U/L])^{1/2}). Patients with FIB-4 ≥ 3.25 were classified as having advanced fibrosis/cirrhosis [1]. The diagnosis of HCC was confirmed according to international guidelines such as spiral computed tomography (CT), magnetic resonance imaging (MRI), and biopsy [15,16]. The follow-up time was calculated from the date of anti-viral treatment at M6 to HCC diagnosis or the date of the last follow-up on 25 October 2021. HCV RNA and HCV genotype were assayed using a real-time PCR assay (RealTime HCV; Abbott Molecular, Des Plaines, IL, USA; detection limit, 12 IU/mL). All protocols were approved by the ethical committee of Kaohsiung Medical University Hospital based on the International Conference on Harmonization for Good Clinical Practice. The stored plasma was extracted from patients with CHC after they provided written informed consent from Kaohsiung Medical University between October 2009 and December 2016.

2.2. MicroRNA Extraction from Plasma

Circulating Let-7 family levels were measured at the initiation of antiviral treatment and 6 months after the end of treatment. Total RNA was extracted from 200 µL of plasma samples using 1 mL Trizol LS reagent and synthetic C. elegans Cel-39 as a spike-in control (Thermo Scientific, Wilmington, DE, USA), according to the manufacturer’s protocol as described previously [11].

2.3. Quantification of Circulating miRNAs

Two steps of Real-time PCR were performed on 20 ng of transcribed total RNA using the TaqMan MicroRNA Reverse Transcription kit and TaqMan® Universal PCR Master Mix II, without uracil N-glycosylase (Thermo Fisher Scientific), according to the manufacturer’s instructions. TaqMan microRNA assays (assay ID): hsa-let-7a (000377), hsa-let-7b (002619), hsa-let-7c (000379), hsa-let-7d (002283), hsa-let-7e (002406), hsa-let-7f (000382), hsa-let-7g (002282), hsa-let-7i (002221), hsa-miR-98 (000577), and cel-miR-39-3p (000200) were used in the assay. All PCR reactions were performed on the 7900HT system (Applied Biosystems, Foster City, CA, USA) under the following conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The relative expression level of each Let-7 member was determined using the comparative CT method, which was defined as 2^{-\Delta Ct}, where \Delta Ct = Ct of the Let-7 member—Ct of cel-39 as described previously [11].

2.4. Statistical Analysis

Statistical analyses were performed using JMP 12.0 (SAS Institute, Cary, NC, USA). Graphs were generated using GraphPad Prism software (version 7.0; San Diego, CA, USA). Categorical variables and continuous variables were respectively calculated using chi-squared with Fisher’s exact test and Student’s t-test or ANOVA adjusted for multiple tests with Dunn-Bonferroni correction. The relationships between the Let-7 family members and different clinical parameters were analyzed using Pearson’s correlation coefficient analysis. Circulating Let-7 family levels were used to predict HCC development in CHC patients using Cox’s regression method and Kaplan-Meier survival analysis method. Statistical significance was set at \( p < 0.05 \).

3. Results

3.1. Characteristics of Patients with CHC

The mean time of HCC development after anti-viral treatment was 4.14 years (SD: 2.63), with patients having significantly higher age (57.87 ± 8.30 years, \( p = 0.0087 \)), FIB-4 > 3.25 score proportion (\( p < 0.0001 \)), AFP (0.0063), AST (\( p < 0.0001 \)), ALT (\( p = 0.0008 \)), and GGT levels (\( p = 0.0004 \)), but lower HCV viral loads (\( p = 0.0494 \)), and platelet count (\( p < 0.0001 \)) than the group without HCC development (Table 1).
Cancers 2022, 14, 23

Table 1. Participant CHC patients’ characteristics.

| Parameters                  | Total (n = 227) | Without HCC Development (n = 173) | De Novo HCC (n = 54) | p       |
|-----------------------------|----------------|-----------------------------------|---------------------|---------|
| Age (yr, mean ± SD)         | 55.15 ± 8.75   | 54.31 ± 8.73                      | 57.87 ± 8.30        | 0.0087  |
| Gender (F/M)                | 116/111        | 93/80                             | 23/31               | 0.1515  |
| BMI                         | 25.33 ± 3.60   | 25.40 ± 3.83                      | 25.30 ± 3.05        | 0.9484  |
| Total Viral loads log_{10} (IU/mL) # | 5.62 ± 0.85    | 5.68 ± 0.85                       | 5.42 ± 0.81         | 0.0494  |
| HCV genotype                | (type1/non-type1/unclassified) (123/99/5) (95/76/2) (28/23/3) 0.2510 | (114/122) (67/106) (37/16) <0.0001 |                      |         |
| Follow-up period (year; mean ± SD) | 2.63 <0.0001  | 0.80 0.3629                       | 0.38 0.6392         | 0.2533  |
| Hemoglobin (g/dL)           | 14.03 ± 2.5    | 14.91 ± 3.72                      | 11.98 ± 7.5         | 0.0069  |
| Platelet count (10^3/μL, mean ± SD) | 5532.45 ± 1639.53 | 5503.24 ± 1722.15                | 5226.67 ± 1333.40   | 0.2946  |
| AST ± SD (IU/L)             | 90.36 ± 53.72  | 81.37 ± 43.58                     | 119.72 ± 71.12      | <0.0001 |
| ALT ± SD (IU/L)             | 123.04 ± 69.95 | 114.41 ± 59.71                    | 150.70 ± 94.71      | 0.0008  |
| GGT (IU/L)                  | 68.16 ± 66.36  | 58.82 ± 57.99                     | 96.17 ± 81.12       | 0.0003  |
| WBC                         | 5437.45 ± 1639.53 | 5503.24 ± 1722.15                  | 5226.67 ± 1333.40   | 0.2946  |
| Hb                          | 14.03 ± 1.47   | 14.09 ± 1.50                      | 13.85 ± 1.16        | 0.3457  |
| Follow-up period (year; mean ± SD) | 9.30 ± 4.18    | 10.98 ± 3.06                      | 4.14 ± 2.63         | <0.0001 |
| FIB-4 > 3.25 (yes/no)       | (114/122)      | (67/106)                          | (37/16)             | <0.0001 |
| FIB-4 > 3.25 (yes/no)       | (130/97)       | (102/71)                          | (28/26)             | 0.4924  |
| FIB-4 > 3.25 (yes/no)       | 22.88 ± 55.43  | 16.91 ± 37.02                     | 41.62 ± 89.95       | 0.0063  |
| BMI                         | 25.33 ± 8.75   | 25.40 ± 8.73                      | 25.30 ± 8.30        | 0.9484  |
| Gender (F/M)                | 116/111        | 93/80                             | 23/31               | 0.1515  |
| C-reactive Protein (µg/mL)  | 0.83 ± 0.25    | 0.81 ± 0.23                       | 0.88 ± 0.31         | 0.0609  |
| Let-7a (ng/mL)              | 1.13 ± 1.13    | 27.20 ± 1.11                      | 27.39 ± 1.20        | 0.2533  |

BMI, body mass index; HCC, hepatocellular carcinoma; LC, liver cirrhosis; Cr, creatinine; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count; PLT, platelet count. All values are expressed as the mean ± standard deviation (SD). The p-value was calculated for the continuous variables using the Student’s t-test or Mann–Whitney test, and the χ² test was used for the categorical variables, with α = 0.05. # The HCV virus loads were determined by log transformation.

3.2. Comparison of Expression among Circulating Let-7 Family between Patients with and Those without HCC Development

In Table 2, we investigated the circulating Let-7 family twice, before (baseline) and after (M6) antiviral treatment regimen. There was no significant correlation between circulating Let-7 levels in the pre-antiviral treatment regimen. After antiviral treatment (M6), the circulating let-7a (p = 0.0011), let-7b (p = 0.0015), let-7g (p = 0.0025), and let-7i (p <0.0001) levels were significantly lower than the group without HCC development. We also measured the dynamic change (Δ) in circulating Let-7 levels as post antiviral treatment value (post; M6) minus baseline (pre; baseline) value. After antiviral treatment, there was a significantly lower dynamic change (Δ) in let-7g (p = 0.0025) and let-7i (p = 0.0013) in the de novo HCC group than in the group without HCC development.

Table 2. Circulating Let-7 family expression at baseline and after anti-viral treatment (M6).

| Log_{10}2^- – Delta Ct | Procedure | Without HCC Development (n = 173) | De Novo HCC (n = 54) | p       |
|-------------------------|-----------|-----------------------------------|---------------------|---------|
|                         |           |                                    | De Novo HCC         |         |
| let7a                   | Pre       | −1.89 ± 0.59                      | −1.98 ± 0.50        | 0.2951  |
|                         | Post      | −1.65 ± 0.67                      | −1.97 ± 0.45        | 0.0011  |
| let7b                   | Δ post-pre | 0.24 ± 0.73                      | 0.01 ± 0.59         | 0.0405  |
|                         | Pre       | −1.55 ± 0.59                      | −1.55 ± 0.61        | 0.9684  |
|                         | Post      | −1.31 ± 0.73                      | −1.66 ± 0.54        | 0.0015  |
| let7c                   | Δ post-pre | 0.24 ± 0.82                      | 0.11 ± 0.77         | 0.0062  |
|                         | Pre       | −2.17 ± 0.44                      | −2.20 ± 0.38        | 0.6392  |
|                         | Post      | −1.94 ± 0.48                      | −1.77 ± 0.95        | 0.0787  |
| let7d                   | Δ post-pre | 0.23 ± 0.61                      | 0.43 ± 1.04         | 0.0726  |
|                         | Pre       | −1.90 ± 0.52                      | −1.99 ± 0.44        | 0.2448  |
|                         | Post      | −1.66 ± 0.66                      | −2.04 ± 0.39        | 0.0078  |
|                         | Δ post-pre | 0.23 ± 0.72                      | −0.05 ± 0.48        | 0.0092  |
### Table 2. Cont.

| Log$_{10}$Δ Ct | Procedure | Without HCC Development (n = 173) | De Novo HCC (n = 54) | p |
|---------------|-----------|-----------------------------------|----------------------|---|
|               |           | ∆ post−pre                         |                      |    |
| let7e         | Pre       | −1.68 ± 0.64                      | −1.68 ± 0.56         | 0.9623 |
|               | Post      | −1.48 ± 0.71                      | −1.72 ± 0.85         | 0.0557 |
| let7f         | Pre       | −2.17 ± 0.42                      | −2.25 ± 0.30         | 0.2065 |
|               | Post      | −2.04 ± 0.53                      | −2.20 ± 0.36         | 0.0353 |
| let7g         | Pre       | −1.90 ± 0.57                      | −1.83 ± 0.55         | 0.4272 |
|               | Post      | −1.68 ± 0.67                      | −1.95 ± 0.46         | 0.0053 |
| let7i         | Pre       | −1.80 ± 0.57                      | −1.83 ± 0.59         | 0.7959 |
|               | Post      | −1.53 ± 0.68                      | −1.96 ± 0.52         | <0.0001 |
| miR−98        | Pre       | −2.29 ± 0.34                      | −2.29 ± 0.26         | 0.8889 |
|               | Post      | −2.17 ± 0.44                      | −2.29 ± 0.41         | 0.0803 |
|               | ∆ post−pre| 0.12 ± 0.52                       | −0.003 ± 0.48        | 0.1180 |

Data are presented as the mean ± SD. The change (Δ) denotes post antiviral treatment (post; M6) minus baseline (pre; baseline) value of Let-7 family members and laboratory parameters at post-anti-viral treatment (M6). Δ$2^{\Delta}$Ct (Ct$_{target}$−Ct$_{reference}$) method. * = p < 0.05 following statistical analysis using an ANOVA with Bonferroni correction (α = 0.0056).

3.3. Correlation Analysis between Let-7 Family Members and Laboratory Parameters

Pairwise correlations of Let-7 family members and laboratory parameters (Table 3), showed a meaningful negative correlation between let-7a ($r = -0.1594$, $p = 0.0272$), let-7e ($r = -0.163$, $p = 0.0239$), let-7f ($r = -0.1456$, $p = 0.0439$), and miR-98 ($r = -0.1971$, $p = 0.0062$) with AST were observed. Furthermore, let-7b ($r = -0.2318$, $p = 0.0116$), let-7d ($r = -0.1943$, $p = 0.0116$), let-7i ($r = -0.2439$, $p = 0.0078$), and miR-98 ($r = -0.2242$, $p = 0.0147$) were negatively correlated with GGT. We also observed meaningful positive correlations between platelet count and Let-7a ($r = 0.2989$, $p < 0.0001$), let-7b ($r = 0.3171$, $p < 0.0001$), let-7d ($r = 0.4028$, $p < 0.0001$), let-7e ($r = 0.3096$, $p < 0.0001$), let-7f ($r = 0.2833$, $p < 0.0001$), let-7g ($r = 0.2595$, $p < 0.0001$), let-7i ($r = 0.3847$, $p < 0.0001$), and miR-98 ($r = 0.3015$, $p < 0.0001$), but not let-7c. A negative correlation between FIB-4 score and Let-7 family members (except for let-7c) was also observed. Circulating Let-7 family members were significantly negatively correlated with a FIB-4 score of <3.25 (Table S2).

### Table 3. Pairwise correlation coefficients were calculated for the Let-7 family and laboratory parameters at post-anti-viral treatment (M6).

| Log$_{10}$Δ Ct | AST     | p       | ALT     | p       | GGT     | p       | PLT     | p       | FIB−4 Score | p       |
|---------------|---------|---------|---------|---------|---------|---------|---------|---------|------------|---------|
| let7a         | −0.22 * | 0.0027  | −0.1476 *| 0.0317  | −0.1587 | 0.0946  | 0.317 * | <0.0001 | −0.3088 *  | <0.0001 |
| let7b         | −0.116  | 0.1176  | −0.0334 | 0.6287  | −0.2202 | 0.0197  | 0.3357 *| <0.0001 | −0.3108 *  | <0.0001 |
| let7c         | −0.123  | 0.0975  | −0.1062 | 0.1233  | 0.0623  | 0.5143  | 0.0602  | 0.382   | −0.0414    | 0.5797  |
| let7d         | −0.182 *| 0.0134  | −0.1123 | 0.1031  | −0.1846 | 0.0513  | 0.4361 *| <0.0001 | −0.3644 *  | <0.0001 |
| let7e         | −0.206 *| 0.005   | −0.1126 | 0.1019  | 0.0648  | 0.4974  | 0.3336 *| <0.0001 | −0.3391 *  | <0.0001 |
| let7f         | −0.183 *| 0.0129  | −0.1017 | 0.1399  | −0.1486 | 0.1178  | 0.3247 *| <0.0001 | −0.3144 *  | <0.0001 |
| let7g         | −0.156 *| 0.0348  | −0.067  | 0.3313  | −0.1136 | 0.2332  | 0.2836 *| <0.0001 | −0.3035 *  | <0.0001 |
| let7i         | −0.162 *| 0.028   | −0.1127 | 0.1017  | −0.2294 | 0.015   | 0.3915 *| <0.0001 | −0.3714 *  | <0.0001 |
| miR98         | −0.209 *| 0.0044  | −0.1553 | 0.0237  | −0.1972 | 0.0372  | 0.3238 *| <0.0001 | −0.2736 *  | 0.0002  |

* Statistically significant at $p \leq 0.05$; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase.
3.4. Let-7 Family Performance for Prediction of HCC Development in CHC Patients after Anti-Viral Treatment

We performed univariate Cox regression analysis and found that let7b (median: ≥−1.44 vs. <−1.44, crude HR = 0.48, 95% CI: 0.21–0.67, p = 0.0007), let7d (median: ≥−1.90 vs. <−1.90 crude HR = 0.35, 95% CI: 0.18–0.61, p = 0.0002), let7i (median: ≥−1.696 vs. <−1.696 crude HR = 0.22, 95% CI: 0.18–0.61, p < 0.0001), dynamic change (Δ) in let-7d levels (median ≥0.17 vs. <0.17 crude HR = 0.42, 95% CI: 0.23–0.73, p = 0.0022), and Δlet-7e levels (median: ≥0.15 vs. <0.15 crude HR = 0.37, 95% CI: 0.20–0.65, p = 0.0005) were significant predictors of HCC. We stratified the patients by SVR status and adjusted by age, sex, HCV genotype, FIB-4 ≥3.25, only let7b (median: ≥−1.44 vs. <−1.44, adjusted HR = 0.30, 95% CI: 0.08–0.89, p = 0.0296) and let7i (median: ≥−1.696 vs. <−1.696, adjusted HR = 0.31, 95% CI: 0.08–0.94, p = 0.0372) (Table 4). In the non-SVR group, let7i (median: ≥−1.696 vs. <−1.969, adjusted HR = 0.09, 95% CI: 0.01–0.45, p = 0.0022) showed an 11-fold decreased cumulative probability of HCC development (Figure 1). Together, the findings suggest that let-7i is an independent factor for HCC development in patients with CHC.

Table 4. Let-7 family associated with the development of HCC in the CHC patients after antiviral treatment (M6): Univariate and Multivariate Cox proportional hazard regression.

| Log102^− –Delta Ct | Procedure | HR(95% CI) | p  | Adjusted HR (95% CI) | p  |
|---------------------|-----------|------------|----|----------------------|----|
| let7a               | M6 median: ≥−1.88 vs. <−1.88 | 0.47 (0.26–0.81) | 0.0067 | 0.68 (0.25–1.80) | 0.4490 |
|                     | Δ post(M6)-pre(baseline) | 0.50 (0.28–0.86) | 0.0128 | 0.42 (0.16–1.06) | 0.0669 |
| let7b               | M6 median: ≥−1.44 vs. <−1.44 | 0.48 (0.21–0.67) | 0.0007 | 0.30 (0.08–0.89) | 0.0296 |
|                     | Δ post(M6)-pre(baseline) | 0.70 (0.40–1.20) | 0.1959 | 0.93 (0.37–2.31) | 0.8752 |
| let7c               | M6 median: ≥−2.02 vs. <−2.02 | 1.02 (0.59–1.74) | 0.9521 | 1.62 (0.57–5.32) | 0.3763 |
|                     | Δ post(M6)-pre(baseline) | 1.16 (0.68–2.00) | 0.5809 | 1.72 (0.64–5.44) | 0.2878 |
| let7d               | M6 median: ≥−1.90 vs. <−1.90 | 0.35 (0.18–0.61) | 0.0002 | 0.90 (0.29–2.78) | 0.8591 |
|                     | Δ post(M6)-pre(baseline) | 0.42 (0.23–0.73) | 0.0022 | 0.62 (0.22–1.66) | 0.3405 |
| let7e               | M6 median: ≥−1.67 vs. <−1.67 | 0.47 (0.26–0.82) | 0.0072 | 1.25 (0.43–3.57) | 0.6721 |
|                     | Δ post(M6)-pre(baseline) | 0.37 (0.20–0.65) | 0.0005 | 0.55 (0.20–1.43) | 0.2259 |
| let7f               | M6 median: ≥−2.16 vs. <−2.16 | 0.69 (0.40–1.18) | 0.1778 | 1.84 (0.67–5.35) | 0.2395 |
|                     | Δ post(M6)-pre(baseline) | 0.83 (0.48–1.41) | 0.4954 | 1.42 (0.55–3.85) | 0.4658 |
| let7g               | M6 median: ≥−1.91 vs. <−1.91 | 0.58 (0.33–1.00) | 0.0537 | 0.95 (0.35–2.49) | 0.9208 |
|                     | Δ post(M6)-pre(baseline) | 0.60 (0.34–1.04) | 0.0690 | 1.34 (0.52–3.57) | 0.5473 |
| let7i               | M6 median: ≥−1.696 vs. <−1.696 | 0.22 (0.11–0.41) | <0.0001 | 0.31 (0.08–0.94) | 0.0372 |
|                     | Δ post(M6)-pre(baseline) | 0.53 (0.30–0.92) | 0.0237 | 1.08 (0.41–2.83) | 0.8793 |
| miR-98              | M6 median: ≥−2.235 vs. <−2.235 | 0.85(0.49–1.45) | 0.5538 | 1.81 (0.69–5.08) | 0.2293 |
|                     | Δ post(M6)-pre(baseline) | 0.76(0.44–1.30) | 0.3191 | 1.49 (0.57–4.01) | 0.4121 |

The change (Δ) denotes post antiviral treatment (post; M6) minus baseline (pre; baseline) values of Let-7 level based on the log102^−–Ct (Ct_target−Ct_cyclo) method. The cut-off value was determined by the median value from the distribution of the let-7 expression on the log102^−–delta Ct method. Adjusted by age, sex, HCV genotype, and FIB-4 ≥3.25; * statistically significant at p ≤ 0.05.
4. Discussion

In this study, we investigated the circulating levels of let-7a/b/g/i and found them to be significantly lower in the HCC development group after antiviral treatment. Let-7 is one of the multiple miRNAs that regulate the infection process, becoming downregulated in HCV infection [6,17]. After antiviral treatment, we found that the circulating Let-7 family was higher in patients with CHC with SVR than in non-SVR (Figure S1), but it was still suppressed in CHC patients with HCC development than those without HCC development (Table S2). Let-7 family members in CHC patients belonging to Cluster 1 include let-7a/d/e/g, members in Cluster 2 comprise of let-7b and let-7i, and those in Cluster 3 are let-7c/f/miR-98 [11]. The Kaplan-Meier survival analysis of the let-7 family cluster 1(let-7a, let-7d, let-7e, and let-7g) and cluster 3 (let-7c, let-7f, and miR-98) with HCC development in the SVR and non-SVR groups are shown in Figures S2 and S3, respectively. Thus, cluster 2 may be stable surveillance of blood biomarkers in liver cirrhosis and HCC development.

In this study, we stratified CHC patients with an SVR status and adjusted for age, sex, log HCV RNA, HCV type, and LC (FIB-4 > 3.25) as covariables (Table 4 and S3); let-7i was a useful marker for discriminating CHC patients with HCC development after antiviral treatment. Let-7 (a/d/e/g) expression positively correlated with PLT as HCV infection [11]. After anti-viral treatment, we found that the Let-7 family member significantly, negatively correlated with AST and hepatic fibrosis score (FIB-4). The serum let-7a level is superior to M2BPGi, FIB-4, and APRI and is comparable to liver stiffness in discriminating liver cirrhosis [18]. Moreover, the measurement of let-7a, let-7c, and let-7d levels in extracellular vesicles has no advantage over the direct measurement in plasma [12].

Figure 1. Kaplan-Meier survival analysis of let-7b and let-7i with HCC development in SVR and non-SVR group. Comparison of the cumulative probability of HCC development divided cut-off value from the median value of the distribution of Let-7 expression based on $\log_{10} 2^{\Delta Ct}$ method in (A) let-7b in SVR group, (B) let-7b in the non-SVR group, (C) let-7i in SVR group, and (D) let-7i in the non-SVR group. HR: Hazard ratio; CI: Confidence interval; HCC: Hepatocellular carcinoma.
to M2BPGi, FIB-4, and APRI and is comparable to liver stiffness in discriminating liver cirrhosis [18]. Moreover, the measurement of let-7a, let-7c, and let-7d levels in extracellular vesicles has no advantage over the direct measurement in plasma [12].

HCV-induced oncogenic Lin28B expression was observed by Ali et al. [19]. The human Lin28 family is composed of two homologs, namely Lin28 (also known as Lin28A and Lin28B). Lin28 is specifically expressed in undifferentiated embryonic stem cells. Lin28A/B can recognize two distinct regions of the RNA and inhibits Let-7 in vivo [20]. Lin28A/B functions as a reprogramming factor together with Oct4, Nanog, and Sox2, to regulate the pluripotency of stem cells [21]. Let-7 represses Lin28 expression through its 3’UTR, promotes differentiation, and inhibits self-renewal during the transition of Caenorhabditis elegans larvae to adulthood [22,23]. Lin28 promotes transformation and is associated with advanced human malignancies [24]. Lin28B overexpression has been noted in most HCC cell lines and clinical samples [25].

In contrast, a previous study showed that let-7b has a significant anti-HCV effect [26] and interferon-alpha (IFNa) rapidly modulates the expression of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1 [27]. Furthermore, let-7g may act as a tumor suppressor gene that inhibits HCC cell proliferation by downregulating c-Myc and upregulating the tumor suppressor gene p16 (INK4A) [28]. Loss of let-7 enhances oncogene RAS and HMGA2 expression, which also promotes “stemness” by repressing self-renewal and promoting differentiation in tumor-initiating cells [29].

Chronic inflammation is a key promotor of cancer. Almost 30% of cancers have been attributed to chronic infections, 30% to environmental factors, and 35% to dietary factors [30]. It is noteworthy that Let-7 can directly repress TLR4 through 3’UTR post-transcriptional regulation, reducing NF-κB activity (Teng et al., 2013). Overexpression of TLR4 in CHC patients is correlated with the inflammatory score and degree of fibrosis [31]. TLR4 plays an important role in the pathogenesis of HCV-related chronic liver disease [32]. Let-7 also directly inhibits IL-6 expression through Ras and NF-κB pathways to prevent cell transformation [33]. Thus, Let-7 regulates chronic inflammation to prevent tumorigenesis.

This study had several limitations. It is known that the combination of AFP, AFP-L3, and DCP had greater predictive power than any individual marker. AFP levels were not available after anti-viral treatment. DCP was not routinely used in Taiwan before 2020. AFP-L3 is not available clinically in Taiwan. Therefore, we cannot compare the advantages and disadvantages of surrogate biomarkers. However, SVR rates of interferon-alpha treatment with immune modulation effects were lower than those of direct antiviral agents, which have 95–99% SVR rates [34], and have been permitted by the Taiwan National Health Insurance Administration Ministry of Health and Welfare since 2017. Even though post-DAA-SVR HCC development patients are difficult to obtain, a high fibrosis stage is also significantly associated with an elevated risk of HCC onset [35]. The current study demonstrated that Let-7 was significantly negatively correlated with the FIB-4 score in the FIB-4 score <3.25 group. Let-7 directly represses TGF-β1 receptor 1 (TGFBR1) expression in the kidney [36], suggesting that Let-7 regulates fibrogenesis in the liver.

5. Conclusions

The main findings in the study were that the let-7i levels are early predictors of HCC development at post-anti-viral treatment and that circulating let7i levels may be of use in the early surveillance of CHC with HCC risk.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14082023/s1. Figure S1: Scatter plots comparing the pre-treatment (baseline) and post-treatment (M6) circulating Let-7 family expression between SVR and non-SVR groups among the de novo HCC and non-HCC CHC patients, Figure S2: Kaplan-Meier survival analysis of let-7a, let-7d, let-7e, and let-7g (belong to Cluster 1) with HCC development in SVR and non-SVR group, Figure S3: Kaplan-Meier survival analysis of let-7c, let-7f, and miR-98 (belong to Cluster 3) with HCC development in the SVR and non-SVR groups, Table S1: De novo HCC patients (n = 54) characteristics by BCLC stage, Table S2: Correlation coefficients were calculated
for the let-7 family and the FIB-4 score of post-anti-viral treatment was stratified by a FIB-4 score of 3.25 (M6), Table S3: Let-7 family associated with the development of HCC in the CHC patients with non-SVR after antiviral treatment (M6). Multivariate Cox proportional hazard regression model.

**Author Contributions:** Investigation, Y.-S.T.; Formal analysis, Y.-S.T. and P.-C.T.; Patient sample collection, M.-L.Y. (Ming-Lun Yeh), C.-I.H., C.-F.H., M.-H.H., T.-W.L., Y.-H.L., P.-C.L., Z.-Y.L., S.-C.C., J.-F.H., C.-Y.D., M.-L.Y. (Ming-Lung Yu), and W.-L.C.; Writing—Original Draft Preparation; Y.-S.T., C.-Y.D., and M.-L.Y. (Ming-Lung Yu); Writing—Review and Editing, C.-Y.D. and M.-L.Y. (Ming-Lung Yu). All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by grants from the National Science Council of Taiwan (grant numbers MOST110-2314-B-037-119 and MOST110-2635-B-037-002) and Kaohsiung Medical University Hospital (grant numbers KMUH107-7R08, KMUH109-9R06, KMUH-DK(C)110011, KMUH-DK(B)111002-I, KMUH-DK(C)111004, and KMUH-DK(C)-111006).

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by Kaohsiung Medical University Hospital based on the International Conference on Harmonization for Good Clinical Practice (KMUHIRB-980176, KMUHIRB-20120097, KMUHIRB-20140054, KMUHIRB-E(I)-20180107).

**Informed Consent Statement:** According research participants’ identification code numbers are anonymized (using nonidentifying codes), the Institutional Review Board relinquished the need for written informed consent.

**Data Availability Statement:** The data presented in this study are available in this article.

**Acknowledgments:** Taiwan Liver Research Foundation (TLRF) provides free liver disease surveillance and health education lectures in the local community.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Ioannou, G.N. Hcc surveillance after SVR in patients with F3/F4 fibrosis. *J. Hepatol.* 2021, 74, 458–465. [CrossRef] [PubMed]
2. Donato, F.; Tagger, A.; Gelatti, U.; Parrinello, G.; Boffetta, P.; Albertini, A.; Decarli, A.; Trevisi, P.; Ribero, M.L.; Martelli, C.; et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. *Am. J. Epidemiol.* 2002, 155, 323–331. [CrossRef] [PubMed]
3. Hsu, W.F.; TsaI, P.C.; Chen, C.Y.; Tseng, K.C.; Kuo, H.T.; Hung, C.H.; Tung, S.Y.; Wang, J.H.; Chen, J.J.; et al. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). *J. Gastroenterol. Hepatol.* 2021, 36, 2884–2892. [CrossRef] [PubMed]
4. Besheer, T.; Elalfy, H.; Abd El-Maksoud, M.; Abd El-Razek, A.; Taman, S.; Zalata, K.; Elkashef, W.; Elshahawy, H.; Raafat, D.; et al. Diffusion-weighted magnetic resonance imaging and micro-RNA in the diagnosis of hepatic fibrosis in chronic hepatitis C virus. *World J. Gastroenterol.* 2019, 25, 1366–1377. [CrossRef]
5. Biselli, M.; Conti, F.; Gramenzi, A.; Frigerio, M.; Cucchetti, A.; Fatti, G.; D’Angelo, M.; Dall’Agata, M.; Giannini, E.G.; Farinati, F.; et al. A new approach to the use of alpha-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. *Br. J. Cancer* 2015, 112, 69–76. [CrossRef]
6. Li, Q.; Lowey, B.; Sodroski, C.; Krishnamurthy, S.; Aaloo, H.; Cha, H.; Chiu, S.; El-Diwany, R.; Ghany, M.G.; Liang, T.J. Cellular microRNA networks regulate host dependency of hepatitis C virus infection. *Nat. Commun.* 2017, 8, 1789. [CrossRef]
7. Hou, J.; Lin, L.; Zhou, W.; Wang, Z.; Ding, G.; Dong, Q.; Qin, L.; Wu, X.; Zheng, Y.; Yang, Y.; et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. *Cancer Cell* 2011, 19, 232–243. [CrossRef]
8. Schueller, F.; Roy, S.; Vucur, M.; Trautwein, C.; Luedde, T.; Roderburg, C. The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. *Int. J. Mol. Sci.* 2018, 19, 261. [CrossRef]
9. Kumar, M.S.; Erkeland, S.J.; Pester, R.E.; Chen, C.Y.; Ebert, M.S.; Sharp, P.A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. *Proc. Natl. Acad. Sci. USA* 2008, 105, 3903–3908. [CrossRef]
10. Mayr, C.; Hemann, M.T.; Bartel, D.P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. *Science* 2007, 315, 1576–1579. [CrossRef]
11. Tsai, Y.S.; Yeh, M.L.; Tsai, P.C.; Huang, C.I.; Huang, C.F.; Hsieh, M.H.; Liu, T.W.; Lin, Y.H.; Liang, P.C.; Lin, Z.Y.; et al. Clusters of circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. *Int. J. Mol. Sci.* 2020, 21, 4945. [CrossRef] [PubMed]
12. Matsuura, K.; De Giorgi, V.; Schechterly, C.; Wang, R.Y.; Farci, P.; Tanaka, Y.; Alter, H.J. Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C. *Hepatology* 2016, 64, 732–745. [CrossRef] [PubMed]
13. Schwarzenbach, H.; Nishida, N.; Calin, G.A.; Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. *Nat. Rev. Clin. Oncol.* 2014, 11, 145–156. [CrossRef] [PubMed]

14. Huang, J.T.; Liu, S.M.; Ma, H.; Yang, Y.; Zhang, X.; Sun, H.; Zhang, X.; Xu, J.; Wang, J. Systematic review and meta-analysis: Circulating microRNAs for diagnosis of hepatocellular carcinoma. *J. Cell. Physiol.* 2016, 231, 328–335. [CrossRef] [PubMed]

15. Heimbach, J.K.; Kulik, L.M.; Finn, R.S.; Sirlin, C.B.; Abecasis, M.M.; Roberts, L.R.; Zhu, A.X.; Murad, M.H.; Marrero, J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018, 67, 388–380. [CrossRef]

16. Omata, M.; Lesmana, L.A.; Tateishi, R.; Chen, P.J.; Lin, S.M.; Yoshida, H.; Kudo, M.; Lee, J.M.; Choi, B.L.; Poon, R.T.; et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol. Int.* 2010, 4, 439–474. [CrossRef]

17. Chou, W.W.; Huang, C.F.; Yeh, M.L.; Tsai, Y.S.; Hsieh, M.Y.; Huang, C.I.; Huang, J.F.; Tsai, P.C.; Hsi, E.; Juo, S.H.; et al. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication. *J. Mol. Med.* 2016, 94, 311–320. [CrossRef]

18. Matsuura, K.; Aizawa, N.; Enomoto, H.; Nishiguchi, S.; Toyoda, H.; Kumada, T.; Iio, E.; Ito, K.; Ogawa, S.; Isogawa, M.; et al. Circulating let-7 Levels in Serum Correlate with the Severity of Hepatic Fibrosis in Chronic Hepatitis C. *Open Forum Infect Dis.* 2018, 5, ofy268. [CrossRef]

19. Ali, N.; Allam, H.; May, R.; Sureban, S.M.; Bronze, M.S.; Bader, T.; Umar, S.; Anant, S.; Houchen, C.W. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. *J. Virol.* 2011, 85, 12292–12303. [CrossRef]

20. Nam, Y.; Chen, C.; Gregory, R.I.; Chou, J.J.; Sliz, P. Molecular basis for interaction of let-7 microRNAs with Lin28. *Cell* 2011, 147, 1080–1091. [CrossRef]

21. Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R.; et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 2007, 318, 1917–1920. [CrossRef] [PubMed]

22. Moss, E.G.; Lee, R.C.; Ambros, V. The cold shock domain protein LIN-28 controls developmental timing in *C. elegans* and is regulated by the lin-4 RNA. *Cell* 1997, 88, 637–646. [CrossRef]

23. Moss, E.G.; Tang, L. Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementarity sites. *Dev. Biol.* 2003, 258, 432–442. [CrossRef]

24. Viswanathan, S.R.; Powers, J.T.; Einhorn, W.; Hoshida, Y.; Ng, T.L.; Toftanin, S.; O’Sullivan, M.; Lu, J.; Phillips, L.A.; Lockhart, V.L.; et al. Lin28 promotes transformation and is associated with advanced human malignancies. *Nat. Genet.* 2009, 41, 843–848. [CrossRef]

25. Guo, Y.; Chen, Y.; Ito, H.; Watanabe, A.; Ge, X.; Kodama, T.; Aburatani, H. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. *Gene* 2006, 384, 51–61. [CrossRef]

26. Cheng, J.C.; Yeh, Y.J.; Tseng, C.P.; Hsu, S.D.; Chang, Y.L.; Sakamoto, N.; Huang, H.D. Let-7b is a novel regulator of hepatitis C virus infection. *Cell. Mol. Life Sci.* CMLS 2012, 69, 2621–2633. [CrossRef]

27. Cheng, M.; Si, Y.; Niu, Y.; Liu, X.; Li, X.; Zhao, J.; Jin, Q.; Yang, W. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGFBP1. *J. Virol.* 2013, 87, 9707–9718. [CrossRef]

28. Lan, F.F.; Wang, H.; Chen, Y.C.; Chan, C.Y.; Ng, S.S.; Li, K.; Xie, D.; He, M.L.; Lin, M.C.; Kung, H.F. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). *Int. J. Cancer* 2011, 128, 319–331. [CrossRef]

29. Bussing, I.; Slack, F.J.; Grosshans, H. Let-7 microRNAs in development, stem cells and cancer. *Trends Mol. Med.* 2008, 14, 400–409. [CrossRef]

30. Aggarwal, B.B.; Vijayalekshmi, R.V.; Sung, B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. *Clin. Cancer Res.* 2009, 15, 425–430. [CrossRef]

31. Vespasiani-Gentilucci, U.; Carotti, S.; Onetti-Muda, A.; Perrone, G.; Ginanni-Corradini, S.; Latasa, M.U.; Avila, M.A.; Carpino, G.; Picardi, A.; Morini, S. Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease. *Mod. Pathol.* 2012, 25, 576–589. [CrossRef] [PubMed]

32. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. *Cell* 2010, 140, 883–899. [CrossRef] [PubMed]

33. Iliopoulos, D.; Hirsch, H.A.; Struhl, K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. *Cell* 2009, 139, 693–706. [CrossRef] [PubMed]

34. Yu, M.L.; Chen, P.J.; Dai, C.Y.; Hu, T.H.; Huang, C.F.; Huang, Y.H.; Hung, C.H.; Lin, C.Y.; Liu, C.H.; Liu, C.J.; et al. 2020 taiwan consensus statement on the management of hepatocellular carcinoma: Part (II) special populations. *J. Formos. Med. Assoc.* 2020, 119, 1135–1157. [CrossRef]

35. Conti, F.; Buonfiglioli, F.; Scuteri, A.; Crespi, C.; Bolondi, L.; Caraceni, P.; Foschi, F.G.; Lenzi, M.; Mazzella, G.; Verucchi, G.; et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J. Hepatol.* 2016, 65, 727–733. [CrossRef]

36. Wang, B.; Jha, J.C.; Hagiwara, S.; McClelland, A.D.; Jandelet-Dahm, K.; Thomas, M.C.; Cooper, M.E.; Kantharidis, P. Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. *Kidney Int.* 2014, 85, 352–361. [CrossRef]